Discovery Matters

Discovery Matters
  • ٤٫٧ (١٩)
  • علوم حياة
  • يتم التحديث كل أسبوعين
Discovery Matters

A collection of stories and insights on matters of discovery that advance life sciences. Brought to you by the curious people at Cytiva.

  1. 98. Detective work in Parkinson's Disease

    قبل يوم واحد

    98. Detective work in Parkinson's Disease

    In this episode of Discovery Matters we delve into groundbreaking advancements in Parkinson’s disease research. Dodi and Conor transport us to the frontier of medical innovation, exploring the latest discoveries and techniques that hold promise for early diagnosis and treatment of Parkinson’s disease. Show notes • Decet, Marianna et al. ‘A candidate loss-of-function variant in SGIP1 causes synaptic dysfunction and recessive parkinsonism’, Cell Reports Medicine, Volume 5, Issue 10. • Hällqvist, J., Bartl, M., Dakna, M. et al. ‘Plasma proteomics identify biomarkers predicting Parkinson’s disease up to 7 years before symptom onset’. Nat Commun 15, 4759 (2024). • Roald Dahl's Marvellous Children's Charity Keywords: non-invasive procedure, early diagnosis, synaptic homeostasis, Parkinsonism, biomarkers, machine learning, REM sleep disorder, inflammatory pathways, dopaminergic cells, predictive diagnostics, early intervention.

    ٢٦ من الدقائق
  2. 97. Re-run: The discovery of Protein A

    ٢٥ جمادى الأولى

    97. Re-run: The discovery of Protein A

    In this re-released episode we revisit protein A. We will dive back into the history and science of protein A. But what exactly sets protein A apart? Is it really the top choice for antibody purification because of its alphabetical ranking, or is there more to the story? And what about its counterparts, proteins G and L?

    ١٥ من الدقائق
  3. 96. Re-run: Tea, jam and protein separation

    ١٩ جمادى الأولى

    96. Re-run: Tea, jam and protein separation

    As we approach our one hundredth episode, travel back with us to the origins of the podcast in our premiere episode, "Team and Jam and Protein Separation." In this debut, we explored the vital process of protein separation—an essential technique in biochemistry and pharmaceuticals that continues to impact human health in significant ways.

    ١٨ من الدقائق
  4. 94. Discovery Maker: Dr Michael Houghton

    ١١ ربيع الآخر

    94. Discovery Maker: Dr Michael Houghton

    Dive into the fascinating world of virology as we welcome Nobel Prize-winning virologist Dr. Michael Houghton on this episode of Discovery Matters. We explore Dr. Houghton's groundbreaking work in identifying the hepatitis C virus (HCV) and his enduring quest to combat this global health threat. From the monumental discovery of HCV in 1982 to the revolutionary diagnostic tests that nearly eradicated transfusion-related hepatitis C by the mid-1990s, Dr. Houghton provides an engaging and insightful journey through decades of scientific innovation. Show notes Richard D Roberts, Patrick C Kyllonen, ‘Morningness–eveningness and intelligence: early to bed, early to rise will likely make you anything but wise!’ Personality and Individual Differences, Volume 27, Issue 6, 1999. https://doi.org/10.1016/S0191-8869(99)00054-9. Taquet, MaximeLone, Nazir et al. ‘Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK.’ The Lancet Psychiatry, Volume 11, Issue 9. https://doi.org/10.1016/S2215-0366(24)00214-1

    ١٨ من الدقائق
  5. 93. How sustainable is biopharma?

    ٢٣ ربيع الأول

    93. How sustainable is biopharma?

    Eco-design, collaboration, circular economy. These are the bywords of sustainability in biopharma. Join Ryan Walker, Senior Director of Sustainability at Cytiva, and Aude Arkham, Global Head of Eco Design and Circular Economy at Sanofi, as they explore how eco-design and circular economy initiatives are shaping the future of healthcare. We delve into challenges, achievements, and the transformational potential of sustainability efforts within biopharma. From Sanofi’s life cycle assessments to industry-wide data difficulties, this episode navigates the complex landscape of creating greener solutions without compromising innovation and compliance.

    ٢٧ من الدقائق
  6. 92. Big data, AI, and the problem of averages

    ٢ ربيع الأول

    92. Big data, AI, and the problem of averages

    In this episode of "Discovery Matters," we dive into the powerful intersection of big data and artificial intelligence. Joined by Matej Macak, a partner from McKinsey, we unravel how AI and machine learning are revolutionizing our approach to finding new, effective medications. With Tom Yankeelov, Professor of Biomedical Engineering, Diagnostic Medicine, Oncology at the University of Texas for Austin, we'll explore the "problem of averages" and much more.

    ٢٦ من الدقائق
  7. 91. The body as a bioreactor

    ١٨ صفر

    91. The body as a bioreactor

    What does 'the body as a bioreactor' mean? In this discussion how scientists use the body's machinery to produce therapeutic proteins. Scott Ripley, General Manager of Nucleic Acids at Cytiva, explains that traditional bioprocessing uses external bioreactors, while the new approach leverages the body's natural processes. This method offers benefits like longer protein half-life and the ability to express multiple proteins simultaneously. Justin Eyquem, assistant professor at University of California San Francisco, discusses the potential of in vivo CAR T cell therapy, which could simplify manufacturing and reduce costs. Both approaches face challenges in quality assurance and regulatory approval but hold promise for personalized and more effective treatments.

    ٣٤ من الدقائق
  8. 90. Advanced therapies (Part 2)

    ٤ صفر

    90. Advanced therapies (Part 2)

    We're diving into advanced therapies with industry leaders. Emmanuel Abate, President of Genomic Medicine at Cytiva discussed the strategies to accelerate clinical work and reduce costs. Nathaniel Wang, CEO and Co-Founder of Replicate Bioscience highlighted their ground breaking self-replicating RNA technology, showcasing impressive clinical results for a rabies vaccine. Both experts emphasized the momentum in biotech, the potential of AI in advancing science, and the importance of making innovative therapies accessible globally. Stay tuned for these insights. Show notes Beneath Everest, a lone caretaker struggles to keep one of the world’s highest laboratories alive Integrating human endogenous retroviruses into transcriptome-wide association studies highlights novel risk factors for major psychiatric conditions Keywords: vaccines, advanced therapies, mRNA, manufacturing, technology, patients, innovation, new modalities.

    ٢١ من الدقائق
مشاهدة الكل (٩٨)

مقطع ترويجي

٤٫٧
من ٥
‫١٩ من التقييمات‬

حول

A collection of stories and insights on matters of discovery that advance life sciences. Brought to you by the curious people at Cytiva.

المعلومات

  • صناع العمل
    Discovery Matters
  • سنوات النشاط
    ١٤٤٠ هـ - ١٤٤٦ هـ
  • الحلقات
    ٩٨
  • التقييم
    ملائم
  • حقوق النشر
    © 195688
  • موقع البرنامج على الويب
    Discovery Matters

قد يعجبك أيضًا

للاستماع إلى حلقات ذات محتوى فاضح، قم بتسجيل الدخول.

اطلع على آخر مستجدات هذا البرنامج

قم بتسجيل الدخول أو التسجيل لمتابعة البرامج وحفظ الحلقات والحصول على آخر التحديثات.
تحديد بلد أو منطقة

أفريقيا والشرق الأوسط، والهند

آسيا والمحيط الهادئ

أوروبا

أمريكا اللاتينية والكاريبي

الولايات المتحدة وكندا